Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Stephens Resumes Myriad Genetics (MYGN) at Overweight
May 9, 2013 7:53 AM EDTStephens resumed coverage on Myriad Genetics (NASDAQ: MYGN) with an Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more... More
Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 6c
May 7, 2013 4:29 PM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $148.25 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.... More



